SS-31 research record explained: Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.

Quick answer

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” in a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.¹

This was an open-label study with a small number of participants, and all knew they were receiving the active drug.¹ For Filipino readers, “SS-31: Identifying responders to elamipretide in Barth syndrome” is best read by matching every conclusion to the exact study, population, outcome, and product identity.

What did this SS-31 record actually examine?

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” start with the recorded result, not the marketing version. In a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.¹

Within “SS-31: Identifying responders to elamipretide in Barth syndrome,” The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it.¹ This was an open-label study with a small number of participants, and all knew they were receiving the active drug.¹

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” that boundary keeps one result from becoming a universal promise. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” the clearest route is to separate the result from its interpretation. WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.²

Within “SS-31: Identifying responders to elamipretide in Barth syndrome,” WHO guidance on suspected falsified medical products and regulatory laboratory testing.² Appearance alone cannot authenticate a product or establish a research outcome.²

In “SS-31: Identifying responders to elamipretide in Barth syndrome,” the careful reading is narrower than a social-media headline. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

The plain-language rule for “SS-31: Identifying responders to elamipretide in Barth syndrome” is simple: identify what was measured before asking what it might mean elsewhere. A precise answer can still be interesting; it simply keeps the reader oriented.

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What was the main finding?

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” one precise finding is more useful than a broad slogan. A phase 2 trial of a topical ophthalmic solution of elamipretide in 12 people with Leber hereditary optic neuropathy found no significant difference in best-corrected visual acuity between treated and vehicle eyes over 52 weeks.³

Within “SS-31: Identifying responders to elamipretide in Barth syndrome,” The randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point.³ This was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit.³

That distinction gives “SS-31: Identifying responders to elamipretide in Barth syndrome” a useful answer without making it sound larger than the evidence. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” the study becomes easier to read when its boundaries remain visible. A study record is most useful when its reported result remains attached to the population, design, source identifier, and exact product identity.⁴

Within “SS-31: Identifying responders to elamipretide in Barth syndrome,” Editorial synthesis of the canonical research records and Philippine verification sources.⁴ This synthesis is educational and is not personal medical advice or a product recommendation.⁴

Keeping that boundary visible makes “SS-31: Identifying responders to elamipretide in Barth syndrome” clearer for a general reader. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

A useful magazine explanation of “SS-31: Identifying responders to elamipretide in Barth syndrome” should make the main point easy to find. It should also keep the study boundary close enough that readers do not need to hunt for it.

Which study details change the interpretation?

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” a useful summary begins with the outcome the researchers actually recorded. In a mouse model of ischemic stroke, a combination of elamipretide and nicotinamide mononucleotide (NMN) significantly reduced post-ischemic brain damage and improved neurological deficits compared to either compound alone.⁵

Within “SS-31: Identifying responders to elamipretide in Barth syndrome,” The study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.⁵ This is an animal study, and the result is for the combination, not elamipretide alone.⁵

What should not be borrowed from the result?

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” start with the recorded result, not the marketing version. In a 12-week randomized trial of 12 males with Barth syndrome, the primary endpoints included the distance walked in six minutes and a measure of muscle strength.⁶

Within “SS-31: Identifying responders to elamipretide in Barth syndrome,” The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome.⁶ The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints.⁶

How does the wider evidence sharpen the picture?

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” one precise finding is more useful than a broad slogan. The same long-term Barth syndrome study also reported improvements in three-dimensional echocardiographic measures of left ventricular stroke, end-diastolic, and end-systolic volumes.⁷

Within “SS-31: Identifying responders to elamipretide in Barth syndrome,” The TAZPOWER open-label extension found that 3D left ventricular stroke, end-diastolic, and end-systolic volumes improved, showing significant trends for improvement from baseline to week 168.⁷ These are secondary endpoint findings from a small, open-label study.⁷

A catalog card does not change the evidence boundary in “SS-31: Identifying responders to elamipretide in Barth syndrome”.⁴ It helps readers locate a live item while the article keeps scientific and product questions separate.⁴

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What should Filipino readers verify next?

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” a useful summary begins with the outcome the researchers actually recorded. The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁸

Within “SS-31: Identifying responders to elamipretide in Barth syndrome,” Official Philippine regulatory verification service.⁸ A portal record applies to the exact product or establishment named in that record.⁸

Bottom line

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” this was an open-label study with a small number of participants, and all knew they were receiving the active drug.¹

The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁸ For “SS-31: Identifying responders to elamipretide in Barth syndrome,” this check belongs beside the science rather than underneath it.

For “SS-31: Identifying responders to elamipretide in Barth syndrome,” the sound conclusion keeps the source, study context, and product identity separate.

Frequently asked questions

What is the fastest way to understand SS-31?

In a long-term open-label extension of the TAZPOWER trial, people with Barth syndrome who continued elamipretide showed a cumulative improvement of 96.1 meters on the six-minute walk test over 168 weeks.¹ For “SS-31: Identifying responders to elamipretide in Barth syndrome,” begin there, then keep the study setting and stated limit beside the result instead of jumping to a broader conclusion.

Does one positive finding settle the whole topic?

No. This was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit.³ In “SS-31: Identifying responders to elamipretide in Barth syndrome,” a finding can be useful while remaining narrow, early, or tied to one measured outcome.

Why does the study context matter?

The study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy.⁵ For “SS-31: Identifying responders to elamipretide in Barth syndrome,” changing the population, design, formulation, or outcome changes the question being answered.

What should Filipino readers verify?

The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁸ While reading “SS-31: Identifying responders to elamipretide in Barth syndrome,” check the exact product and establishment details rather than relying on a familiar molecule name.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In “SS-31: Identifying responders to elamipretide in Barth syndrome,” they are live catalog references for navigation. They do not turn a study result into a product claim, prove equivalence, or suggest using the items together.⁴

Sources

Footnotes

1. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The 168-week open-label extension of the TAZPOWER trial reported significant improvements from baseline on the 6MWT at all time points, with a cumulative 96.1 m improvement at week 168 (P = .003). Ten patients entered the extension, and eight completed it. This was an open-label study with a small number of participants, and all knew they were receiving the active drug. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

2. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩² ↩³

3. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.. The randomized, vehicle-controlled trial reported that the change from baseline in BCVA in elamipretide-treated eyes was not significantly different from the vehicle eyes at any time point. This was a small, phase 2 trial, and a post hoc analysis suggested some individuals met criteria for clinically relevant benefit. ↩ ↩² ↩³ ↩⁴

4. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.; Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.; Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

5. Elamipretide (SS-31) and Nicotinamide Mononucleotide (NMN) Combination Therapy Targets TREM2 to Mitigate Post-ischemic Brain Injury in Mice.. The study found that co-administration of SS-31 and NMN significantly attenuated post-ischemic brain damage and ameliorated neurological deficits (P < 0.0001), with effects superior to monotherapy. This is an animal study, and the result is for the combination, not elamipretide alone. ↩ ↩² ↩³ ↩⁴

6. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE). The FDA snapshot summary describes the randomized portion of the SPIBA-201 trial, which evaluated efficacy in 12 patients aged ≥12 years with genetically confirmed Barth syndrome. The snapshot reports the trial design and endpoints but does not provide the numerical results for the primary endpoints. ↩ ↩² ↩³

7. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.. The TAZPOWER open-label extension found that 3D left ventricular stroke, end-diastolic, and end-systolic volumes improved, showing significant trends for improvement from baseline to week 168. These are secondary endpoint findings from a small, open-label study. ↩ ↩² ↩³

8. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩² ↩³ ↩⁴ ↩⁵